Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus TAVIST.
PHENERGAN VC vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine